choc cardiogénique - cemir · 1. dobutamine should be used to treat low cardiac output in...
TRANSCRIPT
![Page 1: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/1.jpg)
Choc cardiogénique
juin 2018
Nadia Aissaoui Réanimation médicale
Hôpital Européen Georges Pompidou Université Paris Descartes INSERM-U970, équipe 4
Diplôme d'études spécialisées complémentaires de Réanimation médicale
![Page 2: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/2.jpg)
Plan
1. Definition and profiles
2. Epidemiology
3. Management
Resuscitation and medical therapy
‒ Inotropes/Vasopressors
‒ Revascularisation
‒ New therapies
Mechanical circulatory support
![Page 3: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/3.jpg)
Cardiogenic shock (CS) definition
![Page 4: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/4.jpg)
Established criteria for the diagnosis of CS are as follows:
(1) Systolic blood pressure less than 90 mmHg for 30 min or mean arterial pressure less
than 65 mmHg for 30 min or vasopressors required to achieve a blood pressure ≥ 90 mmHg;
(2) Pulmonary congestion or elevated left-ventricular filling pressures;
(3) Signs of impaired organ perfusion with at least one of the following criteria: (a)
altered mental status; (b) cold, clammy skin; (c) oliguria; (d) increased serum lactate
![Page 5: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/5.jpg)
What are we talking about ? Spectrum of CS
Atkinson TM et al., J Am Coll Cardiol Intv 2016;9:871–83
![Page 6: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/6.jpg)
Various profiles of severity in cardiogenic shock
Inotrope dependent
Sliding on inotropes
Refractory to inotropes
Introduction of inotropes
![Page 7: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/7.jpg)
Various profiles of severity in cardiogenic shock
![Page 8: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/8.jpg)
Pour modifier les textes :
Menu « Affichage », « Masque », « Masque des diapositives ».
Cliquer dans le bloc texte.
Modifier le texte.
When signs of cardiogenic shock remain despite optimal and maximal conventionnal therapy
No consensus about the definition of optimal and maximal conventionnal therapy
Refractory cardiogenic shock
![Page 9: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/9.jpg)
Pour modifier les textes :
Menu « Affichage », « Masque », « Masque des diapositives ».
Cliquer dans le bloc texte.
Modifier le texte.
Refractory cardiogenic shock
![Page 10: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/10.jpg)
– Multicentre, prospective, observational study conducted between 2010 and 2012
– Patients with either acute coronary syndrome (ACS) or non-ACS aetiologies were enrolled within 6 h from detection of CS: n = 219, mean age 67, 74% men
80%
11%
5%
2% 2%
Acute coronary syndrome
Worsening of chronic heart failure
Tako-Tsubo
Myocarditis Others
Etiologies
![Page 11: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/11.jpg)
11 %
6 %
5 %
5 %
1 %
22 %25 %
25 %
,
Other
Post-cardiac arrest resuscitation syndrome
Fulminant myocarditis
cardiotoxic drug intoxication
arrythmia disorders
Pulmonary embolism
Acute myocardial infarction
Acute decompensated heart failure
Cardiogenic shock n=19,416
![Page 12: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/12.jpg)
Etiologies of CS
Medical cardiogenic shock
– acute myocardial infarction
– fulminant myocarditis
– cardiotoxic drug intoxication
– stress-induced cardiomyopathy
– post-cardiac arrest resuscitation syndrome
– decompensated pulmonary vascular disease
– massive pulmonary embolism
– acute decompensated heart failure
![Page 13: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/13.jpg)
Etiologies of CS
Medical cardiogenic shock
Post-surgical CS after heart surgery (including heart
transplantation)
– acute myocardial infarction
– acute decompensated heart failure
– fulminant myocarditis
– cardiotoxic drug intoxication
– stress-induced cardiomyopathy
– post-cardiac arrest resuscitation syndrome
– decompensated pulmonary vascular disease
– massive pulmonary embolism
![Page 14: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/14.jpg)
0
10
20
30
40
50
60
70
1997-1998n=1488
1999-2000n=1760
2001-2002n=2154
2003-2004n=2448
2005-2006n=2518
2007-2008n=2661
2009-2010n=3004
2011-2012n=3383
P<0.001
Mortality of CS patients admitted in ICUs
– In-ICU Mortality during the period study : 47.4% (9 205/19 416) – Decrease : -5,6 % (95% CI, -7,7 to -3,5) from 50.3% (1997-2002) to 44.8% (2009-2012)
Puymirat E et Aissaoui N., EJHF 2016
![Page 15: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/15.jpg)
0
10
20
30
40
50
60
70
80
90
100
1997-1998n=448
1999-2000n=462
2001-2002n=528
2003-2004n=549
2005-2006n=661
2007-2008n=638
2009-2010n=767
2011-2012n=904
0
10
20
30
40
50
60
70
80
90
100
1997-1998n=55
1999-2000n=93
2001-2002n=62
2003-2004n=58
2005-2006n=59
2007-2008n=72
2009-2010n=92
2011-2012n=94
0
10
20
30
40
50
60
70
80
90
100
1997-1998n=221
1999-2000n=240
2001-2002n=266
2003-2004n=268
2005-2006n=249
2007-2008n=286
2009-2010n=343
2011-2012n=420
0
10
20
30
40
50
60
70
80
90
100
1997-1998n=264
1999-2000n=322
2001-2002n=479
2003-2004n=510
2005-2006n=570
2007-2008n=655
2009-2010n=734
2011-2012n=663
Cardiac arrest
Myocardial infarction
Decompensated heart failure
Pulmonary embolism
P=0.85
P<0.001 P<0.001
P=0.009
Mortality according to the primary diagnosis
Puymirat E et Aissaoui N., EJHF 2016
![Page 16: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/16.jpg)
2 main types of medical CS
Severity
Acute etiology of CS ‒ AMI ‒ Fulminant myocarditis ‒ Drug intoxication ‒ ….
INTERMACS 1/refractory CS
INTERMACS 2
High risk for severe forms of CS, even refractory CS
![Page 17: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/17.jpg)
2 main types of medical CS
Severity
Acute etiology of CS ‒ AMI ‒ Fulminant myocarditis ‒ Drug intoxication ‒ ….
Decompensated advanced heart failure
INTERMACS 1/refractory CS
INTERMACS 2
INTERMACS 3/Inotrope dependence
High risk for severe CS, even refractory CS
More often low-out put syndrome Chronic situation
![Page 18: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/18.jpg)
HR 1.11 (0.65-1.91) P=0.69
No cardiogenic shock Cardiogenic Shock
FAST MI 2005 : 3670 pts CS occurred in 224 (6.1%)
Alive at 30D : 3411 with 99 CS
![Page 19: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/19.jpg)
Median follow-up was 525 (inter-quartile range, 305–1496; range, 92–2400) days
Mirabel M et al., Crit Care Med. 2011;39:1029-35
ICU survival : 68%
Long-term survival : 68%
![Page 20: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/20.jpg)
Among 115 patients, 85 patients (75%)
died at 4 months
Circ Heart Fail. 2009;2:320-4
![Page 21: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/21.jpg)
2 main types of medical CS
Severity
Acute etiology of CS ‒ AMI ‒ Fulminant myocarditis ‒ Drug intoxication ‒ ….
Decompensated advanced heart failure
High risk for severe CS, even refractory CS
More often low-out put syndrome Chronic situation
Long term-prognosis
![Page 22: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/22.jpg)
Sean van Diepen et al. Circulation. 2017;136:e232-e268
![Page 23: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/23.jpg)
Sean van Diepen et al. Circulation. 2017;136:e232-e268
“ CS is a hemodynamic problem only at the very beginning, and soon becomes a very complex
disease, with bacterial translocation, overshooting
inflammation and the development of multiple organ
failure”
Combes et al. ICM. 2016
![Page 24: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/24.jpg)
Circulation. 2017;136:e232–e268
![Page 25: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/25.jpg)
![Page 26: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/26.jpg)
![Page 27: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/27.jpg)
![Page 28: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/28.jpg)
![Page 29: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/29.jpg)
Cardiogenic shock management pathway
Sean van Diepen et al. Circulation. 2017;136:e232-e268
![Page 30: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/30.jpg)
Sean van Diepen et al. Circulation. 2017;136:e232-e268
![Page 31: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/31.jpg)
The optimal first-line vasoactive medication in CS remains unclear
Sean van Diepen et al. Circulation. 2017;136:e232-e268
Inotropes or vasopressors ?
![Page 32: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/32.jpg)
Sean van Diepen et al. Circulation. 2017;136:e232-e268
Copyright © American Heart Association, Inc. All rights reserved.
![Page 33: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/33.jpg)
Sean van Diepen et al. Circulation. 2017;136:e232-e268
Copyright © American Heart Association, Inc. All rights reserved.
We have to
improve the
cardiac pump
function
![Page 34: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/34.jpg)
Effects of Inotropes on Microcirculation in CS
Plos One 2014; 9: e103978.
Thirty patients with cardiogenic shock were included
![Page 35: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/35.jpg)
![Page 36: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/36.jpg)
“Levosimendan did not
significantly reduce all-cause mortality at 180
days or affect any secondary clinical
outcomes”
173 deaths (26%)
185 deaths (28%)
![Page 37: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/37.jpg)
– In the SURVIVE study population (1327), 669 (50%) had received b-blockers within 24 h prior to study drug infusion.
Mebazaa A et al., Eur J Heart Fail. 2009;11: 304-11
For patients who used beta-blockers (n = 669), mortality was significantly lower for levosimendan than dobutamine at day 5 (1.5 vs. 5.1% deaths; HR, 0.29; CI 0.11-0.78, P = 0.01).
![Page 38: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/38.jpg)
![Page 39: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/39.jpg)
1. Dobutamine should be used to treat low cardiac output in
cardiogenic shock (strong agreement)
2. Phosphodiesterase inhibitors or levosimendan should not be used firstline (strong agreement)
3. There is a pharmacodynamic rationale for the use of levosimendan in patients on chronic beta-blocker treatment
![Page 40: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/40.jpg)
Sean van Diepen et al. Circulation. 2017;136:e232-e268
Copyright © American Heart Association, Inc. All rights reserved.
![Page 41: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/41.jpg)
Sean van Diepen et al. Circulation. 2017;136:e232-e268
Copyright © American Heart Association, Inc. All rights reserved.
We have to decrease the peripheral vasodilatation
![Page 42: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/42.jpg)
Norepinephrine in cardiogenic shock ?
De Backer D et al., N Engl J Med. 2010;362:779–89
‒ 1679 patients, of whom 858 were assigned to dopamine and 821 to norepinephrine. ‒ The baseline characteristics of the groups were similar.
![Page 43: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/43.jpg)
Plos One 2014; 9: e103978.
![Page 44: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/44.jpg)
Norepinephrine infusion was associated with - no changes in heart rate, - a significant increase in CI, MAP, SVO2, LVEF, dP/dt max, and SVR - a decrease in lactate level
Beurton A et al., Shock 2016; 46; 214-218
12 pigs with AMI and CS : control group (n = 6), norepinephrine infusion (n = 6)
![Page 45: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/45.jpg)
Tarvasmäki T et al., Crit Care. 2016;20:208
‒ The multinational CardShock study prospectively enrolled 219 patients with CS (80% ACS) ‒ Patients with adrenaline : 46 (21%)
![Page 46: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/46.jpg)
Critical care Med, 2011 ;39:450-5.
![Page 47: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/47.jpg)
Critical care Med, 2011 ;39:450-5.
![Page 48: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/48.jpg)
Critical care Med, 2011 ;39:450-5.
![Page 49: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/49.jpg)
Ten patients survived in the epinephrine group and 11 in the norepinephrine-dobutamine group
Critical care Med, 2011 ;39:450-5.
![Page 50: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/50.jpg)
Epinephrine (adrenaline) should be restricted to patients with persistent hypotension despite adequate cardiac filling pressures and the use of other vasoactive agents, as well as for resuscitation protocols
![Page 51: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/51.jpg)
Norepinephrine should be used to restore perfusion pressure during cardiogenic shock (strong agreement)
Epinephrine can be a therapeutic alternative to the combination of dobutamine and norepinephrine, but is associated with a greater risk of arrhythmia, tachycardia, and hyperlactatemia (weak agreement)
![Page 52: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/52.jpg)
‒ « Inotropes, especially those with adrenergic mechanisms, can cause sinus tachycardia, may induce myocardial ischaemia and arrhythmias.
- There is long-standing concern that they may increase
mortality...”
![Page 53: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/53.jpg)
Sean van Diepen et al. Circulation. 2017;136:e232-e268
Copyright © American Heart Association, Inc. All rights reserved.
![Page 54: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/54.jpg)
Sean van Diepen et al. Circulation. 2017;136:e232-e268
Copyright © American Heart Association, Inc. All rights reserved.
Inhibition of systemic
inflammatory response ?
![Page 55: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/55.jpg)
Standard therapy
N = 15
Standard therapy +
LNAM (1mg/kg and 1 mg/kg/h) N = 15
![Page 56: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/56.jpg)
![Page 57: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/57.jpg)
![Page 58: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/58.jpg)
Sean van Diepen et al. Circulation. 2017;136:e232-e268
![Page 59: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/59.jpg)
1.Frequently altered mental status does not ensure correct spontaneous breathing and preservation of the upper airway, two conditions necessary for the appropriate use of NIV 2. It may be cautiously considered in selected CS patients without severe haemodynamic instability
![Page 60: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/60.jpg)
Suggestions for Clinical Practice
The decision to intubate patients with CS should be based on standard critical care criteria; however, clinicians should be both aware of and prepared for the potential hemodynamic deterioration associated with induction therapies, inappropriate ventilation settings, the transition from spontaneous breathing to positive-pressure ventilation, and vagal stimulation association with endotracheal tube placement
In the absence of high-quality data in the CS population, we suggest that MV modes and settings be adjusted to prevent hypoxemia and hyperoxia, to minimize patient discomfort and ventilator dyssynchrony, and to optimize hemodynamics.
Circulation. 2017;136:e232–e268
![Page 61: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/61.jpg)
Circulation. 2017;136:e232–e268
Among patients with CS, a reported 13% to 28% develop acute kidney injury and up to 20% require renal replacement therapy
Patients needing renal replacement therapy were less likely to survive to hospital discharge and had a higher risk of long-term dialysis and mortality
Patients with CS often do not hemodynamically tolerate fluid shifts that can occur with intermittent hemodialysis.
Instead, continuous renal replacement therapy, is more commonly used for those with CS.
Renal Replacement Therapy
![Page 62: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/62.jpg)
Lauridsen et al. Critical Care (2015) 19:452
Acute kidney injury and renal replacement therapy in CS patients
5079 CS patients with 13 % had AKI-RRT
In-hospital mortality :62 % for AKI-RRT patients, and 36 % for non-AKI-RRT patients. (relative risk = 1.70,
95 % confidence interval (CI): 1.59–1.81).
![Page 63: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/63.jpg)
Circulation. 2017;136:e232–e268
![Page 64: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/64.jpg)
![Page 65: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/65.jpg)
The use of percutaneous coronary intervention dereased the
mortality of patients presenting CS after AMI
Aissaoui N, EHJ 2003 33: 2535-43
486 CS patients (1995-2005)
46.7%
22 %
33.6%
40.5%
302 CS patients (1993-1998)
Hochman J, JAMA 2001 33: 190-192
![Page 66: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/66.jpg)
“Intensive care before coronary angiography of CS secondary to MI should be of the “scoop and run” type. What is important is to transfer the patient alive to the
coronary angiography unit without any delay as a result of an attempt at stabilization.”
![Page 67: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/67.jpg)
![Page 68: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/68.jpg)
Multivessel coronary artery : PCI for culprit lesion or all coronary arteries ?
![Page 69: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/69.jpg)
Patients underwent randomization immediately after diagnostic angiography 1:1 ratio
either PCI of the culprit lesion only immediate multivessel PCI
Patients were eligible for the trial if they had acute myocardial infarction with cardiogenic shock
![Page 70: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/70.jpg)
![Page 71: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/71.jpg)
The composite primary end point of death or renal-replacement therapy had occurred in 158 of the 344 patients (45.9%) in the culprit-lesion-only PCI group and in 189 of the 341 patients (55.4%) in the multivessel PCI group
![Page 72: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/72.jpg)
![Page 73: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/73.jpg)
The place of the fibrinolysis in CS STEMI patients ?
“The ESC guidelines (2012) suggest the use of thrombolysis if angioplasty cannot be performed quickly
(within 2 h), with secondary transfer to a center with a coronary angioplasty and cardiac surgery unit”
![Page 74: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/74.jpg)
Circulation. 2017;136:e232–e268
![Page 75: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/75.jpg)
Various profiles of severity in cardiogenic shock
patients
Inotrope dependent
Sliding on inotropes
The most severe form : Refractory to inotropes
Introduction of inotropes
![Page 76: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/76.jpg)
Various profiles of severity in cardiogenic shock
patients
Introduction of inotropes
![Page 77: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/77.jpg)
![Page 78: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/78.jpg)
Introduction of inotropes
‒ « Inotropes, especially those with
adrenergic mechanisms, can cause sinus tachycardia, may induce myocardial ischaemia and arrhythmias.
- There is long-standing concern that
they may increase mortality...”
To minimize the side effects of catecholamines ?
![Page 79: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/79.jpg)
Thiele H, N Engl J Med. 2012 Oct 4;367(14):1287-96.
A patient was considered to be in cardiogenic shock : ‒ systolic blood pressure < 90 mm Hg for more than 30 min
or needed infusion of catecholamines to maintain SBP > 90 ‒ clinical signs of pulmonary congestion, ‒ and impaired end- organ perfusion
Not eligible for the study if ‒ resuscitation for more than 30 minutes; ‒ mechanical cause of CS ‒ onset of shock more than 12 hours before screening;
![Page 80: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/80.jpg)
The IABP does not modify the prognosis of CS
Thiele H, N Engl J Med. 2012 Oct 4;367(14):1287-96.
Randomized prospective study - 300 pts in the IABP group - 298 pts in the control group
39,7 %
41,3 %
![Page 81: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/81.jpg)
![Page 82: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/82.jpg)
• Intraaortic balloon counterpulsation should not be used in cardiogenic shock in the setting of myocardial infarction managed
effectively and quickly by angioplasty (weak agreement).
![Page 83: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/83.jpg)
Pour modifier les textes :
Menu « Affichage »,
« Masque », « Masque des diapositives ».
Cliquer dans le bloc texte.
Modifier le texte.
. The Impella® Recover LVAD
Reesink et al., Chest 2004, Lemaire A et al., ATS 2014, Seyfarth et al., JACC 2008
‒ Short-term left ventricular support with a flow of 2.5 or 5 l/min (Impella® 2.5 or 5.0, respectively)
‒ A microaxial rotary blood pump is
inserted through the femoral artery and passed retrogradely through the aorta into the left ventricle
![Page 84: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/84.jpg)
Pour modifier les textes :
Menu « Affichage »,
« Masque », « Masque des diapositives ».
Cliquer dans le bloc texte.
Modifier le texte. Impella’s family
![Page 85: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/85.jpg)
25 patients (n 13 IABP, n 12 Impella LP2.5)
![Page 86: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/86.jpg)
Ouweneel et al. J A C C 2 0 1 7; 69: 2 7 8– 8
![Page 87: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/87.jpg)
On the contrary, due to the limited blood blow obtained with the Impella® 2.5 device, the latter is not recommended for cardiac support during cardiogenic
shock.
![Page 88: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/88.jpg)
Various profiles of severity in cardiogenic shock patients
Introduction of inotropes
No mechanical circulatory support
![Page 89: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/89.jpg)
Various profiles of severity in cardiogenic shock patients
Inotrope dependent
Sliding on inotropes
The most severe form : Refractory to inotropes
Introduction of inotropes
Temporary mechanical circulatory support
Long-term
mechanical circulatory support
![Page 90: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/90.jpg)
INTERMACS 1 and 2 patients
Introduction des inotropes Refractaire aux inotropes
![Page 91: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/91.jpg)
Although there is no strong scientific evidence to support routine MCS therapy in
CS patients to date, it can provide emergency circulatory support while a definite solution is
sought
![Page 92: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/92.jpg)
If temporary circulatory support is needed, the use of peripheral extracorporeal membrane oxygenation is preferred (strong agreement).
![Page 93: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/93.jpg)
Veno-arterial Extra-corporal Membrane Oxygenation
Abrams D et al., J Am Coll Cardiol. 2014;63:2769-78
![Page 94: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/94.jpg)
VA-ECMO provides – both respiratory and cardiac
support, – biventricular support, – is easy to insert, even at the
bedside, – stable flow rates, – and is associated with less
organ failure, after implantation compared to large biventricular assist
![Page 95: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/95.jpg)
Day-30 survival 57 %
![Page 96: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/96.jpg)
Schmidt M et al., EHJ published June 17, 2015
Discharge from hospital 1601 (42%)
![Page 97: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/97.jpg)
N = 235
![Page 98: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/98.jpg)
![Page 99: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/99.jpg)
Reported complication rates were frequent :
- Lower extremity ischemia : 16.9%
- Fasciotomy or compartment syndrome : 10.3%
- Lower extremity amputation : 4.7%
- Stroke: 5.9%
- Major or significant bleeding : 40.8%
- Re-thoracotomy for post-cardiotomy bleeding or tamponade : 41.9%
- Significant infection : 30.4%
![Page 100: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/100.jpg)
When ?
![Page 101: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/101.jpg)
Etiology of CS and
Medical history
Biological data and TTE
Clinical parameters
- Clinical signs associated with rapid deterioration of cardiac function - Treatments administered and tolerance
Which parameters to consider to initiate cardiac support ?
– Liver and renal impairment
– TTE data
Before multi-organ failure
develops
![Page 102: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/102.jpg)
3846 cardiogenic shock patients risk factors associated with mortality: – preexisting comorbidities, – pre-ECMO organ failures, – cardiac arrest, – lower pulse pressure, – lower serum bicarbonate
![Page 103: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/103.jpg)
When to initiate ?
![Page 104: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/104.jpg)
The Impella® 5.0 device can be used in the management of cardiogenic shock
complicating myocardial infarction if the surgical team has experience with its
placement (weak agreement).
![Page 105: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/105.jpg)
– In-ICU survival N = 23 (57%) – D-180 survival – N=20 (50%)
![Page 106: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/106.jpg)
Indications of Impella 5.0 in CS patients
« these systems are currently more expensive and are not adapted to patients with severe biventricular failure. »
Post-heart surgery++++
16 patients developing CS or low cardiac output syndrome after being weaned off cardiopulmonary bypass
Survival to 30 days, 3 months, and 1 year was 94%, 81%, and 75%, respectively
![Page 107: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/107.jpg)
Complications related to Impella devices
Ouweneel DM, et al., JACC 2016
Hemolysis
Complications
Bleeding
Vascular complications
Infections
![Page 108: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/108.jpg)
ECMO or Impella 5.0 ?
Respiratory status Right ventricular function
Surgical availabilities
![Page 109: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/109.jpg)
ECMO and Impella
ECMO ECMO and Impella
Jouan J et al. J Heart Lung Transplant. 2010;29:135-6 Cheng A et al., ASAIO J 2013; 59: 533-6
![Page 110: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/110.jpg)
![Page 111: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/111.jpg)
![Page 112: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/112.jpg)
Various profiles of severity in cardiogenic shock
patients
Inotrope dependent
Sliding on inotropes
The most severe form : Refractory to inotropes
Introduction of inotropes
Decompensated of advanced heart failure
INTERMACS 3/Inotrope dependence
![Page 113: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/113.jpg)
![Page 114: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/114.jpg)
Long-term ventricular assist devices
![Page 115: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/115.jpg)
![Page 116: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/116.jpg)
![Page 117: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/117.jpg)
ESC/EACTS Guidelines on myocardial revascularization. EHJ 2014 Levy et al., Annals of Intensive Care 2015
![Page 118: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/118.jpg)
Management in emergency : Cardiologists, ICU physicians
Timing of cardiac device implantation : Cardiologists, ICU physicians, Surgeons
Implantation-Management : Surgeons, ICU physicians
Decision concerning long-term assist device or heart transplantation :
Cardiologists, Transplant team, ICU physicians, Surgeons
[Tertiary centers]
Mobile Unit of Circulatory Assistance
Management of cardiogenic shock need a team with a
comprehensive, structured, multidisciplinary system of care
![Page 119: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/119.jpg)
Key role of the intensivists
![Page 120: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/120.jpg)
Conclusions
− Several profiles of cardiogenic shock − Major concern : mortality rate around 40 to 60 % at one-month
− Lack of evidence for medical therapy and the choice of inotrope
− Early implantation of MCS without forgetting their complications
− Impella 5.0 assists the LV whereas ECMO is an extracorporeal membrane oxygentation
− Management of cardiogenic shock need a team with a comprehensive, structured, multidisciplinary system of care
![Page 121: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/121.jpg)
Annexes
![Page 122: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/122.jpg)
Other therapies
![Page 123: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/123.jpg)
Corticosteroid Insufficiency in Cardiogenic
Shock Patients
Ducrocq N et al., Shock. 2017 Dec 26.
42%
32%
![Page 124: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/124.jpg)
Corticosteroid Insufficiency in Cardiogenic
Shock Patients : prognostic value ?
Ducrocq N et al., Shock. 2017 Dec 26.
![Page 125: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/125.jpg)
Corticosteroid Insufficiency in Cardiogenic Shock
Patients : prognostic value ?
Ducrocq N et al., Shock. 2017 Dec 26.
Patients with a T0 TC 34 μg/dL or less and Δ max greater than 9 μg/dL appeared to have the most favorable survival (91%)
Corticosteroid therapy was associated with an increased mortality (P = .03)
![Page 126: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/126.jpg)
• Application of hypothermia in non-resuscitated CS patients may also be beneficial from pathophysiological
considerations with multiple beneficial targets
![Page 127: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/127.jpg)
![Page 128: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/128.jpg)
![Page 129: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/129.jpg)
![Page 130: Choc cardiogénique - CeMIR · 1. Dobutamine should be used to treat low cardiac output in cardiogenic shock (strong agreement) 2. Phosphodiesterase inhibitors or levosimendan should](https://reader033.vdocuments.mx/reader033/viewer/2022050607/5fae2eaa090bae2a6824757a/html5/thumbnails/130.jpg)